Study on the clinical effect of ranitidine combined with omeprazole in the treatment of peptic ulcers

The clinical safety and efficacy of a novel pharmaceutical material (ranitidine combined with omeprazole) for treating peptic ulcers was analyzed using gastroscopy. The subjects were from the Department of Gastroenterology, Nankai hospital, Tianjin, China. Gastroscopy was performed from March 2017 to March 2018. A 100 eligible patients with gastric ulcers were selected. The patients with peptic ulcers were randomly divided into two groups with 50 patients each. For the control group, 150 mg ranitidine was administered orally, twice a day before meals, for four weeks. For the combined group, 150 mg ranitidine was administered orally, twice a day before meals, along with 20 mg omeprazole once a day, for four weeks. The clinical efficacy of the therapy, disease recurrence, and adverse reactions were compared between the two groups. The antacid effect of combined therapy was stronger and longer lasting when compared with the control group (P < 0.05). After six months of follow-up, the Helicobacter pylori (HP) clearance in the combined treatment group was more efficient than in the control group (P < 0.05). Serious adverse reactions were not found in both the groups. Ranitidine combined with omeprazole is effective and safe in the treatment of peptic ulcers and worthy of clinical application.